Advertisement
Screener

Vir Biotechnology, Inc. (VIR) Graph

VIR Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $238.95M; Cost of revenue $0.00; Research and development $135.28M; Selling, general and administrative $30.20M.
  • 2026-03-31: Revenue -$29.00K; Cost of revenue (m); Research and development $108.92M; Selling, general and administrative $23.34M.
  • 2025-12-31: Revenue $64.07M*; Cost of revenue (m); Research and development $88.35M*; Selling, general and administrative $23.62M*.
  • 2025-09-30: Revenue $240.00K; Cost of revenue (m); Research and development $151.46M; Selling, general and administrative $22.23M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

VIR revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Grant$11.00KLicense AndCollaboration Revenue$238.94MOther Revenue$0.00Revenue$238.95MCost of revenue$0.00Operating income$73.47MOther income, net-$451.00KResearch & development$135.28MSelling, general& administrative$30.20MPre-tax income$80.26MIncome tax$179.00KNet income$80.08M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

VIR revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$238.95MRevenue$238.95MCost of revenue$0.00Operating income$73.47MOther income, net-$451.00KResearch & development$135.28MSelling, general& administrative$30.20MPre-tax income$80.26MIncome tax$179.00KNet income$80.08M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$238.95M$0.00$135.28M$30.20M(m)$179.00K$80.08M
2026-03-31-$29.00K(m)$108.92M$23.34M(m)$170.00K-$125.69M
2025-12-31$64.07M*(m)$88.35M*$23.62M*(m)-$137.00K*-$42.92M*
2025-09-30$240.00K(m)$151.46M$22.23M(m)$168.00K-$163.14M
2025-06-30$1.21M$11.00K$97.51M$22.28M(m)$170.00K-$110.96M
2025-03-31$3.03M$0.00$118.64M$23.94M(m)$16.00K-$120.97M
2024-09-30$2.38M$50.00K$195.18M$25.74M(m)$177.00K-$213.72M
2024-06-30$3.08M$52.00K$105.11M$30.27M(m)-$1.51M-$138.38M
2024-03-31$56.38M$59.00K$100.13M$36.32M(m)$276.00K-$65.28M
2023-09-30$2.64M$38.00K$145.03M$40.93M(m)-$3.21M-$163.41M
2023-06-30$3.80M$22.00K$168.08M$45.51M(m)-$2.85M-$194.78M
2023-03-31$62.96M$1.91M$157.64M$46.78M(m)-$2.23M-$140.96M
2022-09-30$374.56M$22.25M$114.17M$43.17M(m)$42.42M$175.31M
2022-06-30-$40.63M$27.92M$115.08M$41.59M(m)-$157.23M-$76.49M
2022-03-31$1.23B$90.15M$90.23M$38.26M(m)$403.29M$518.62M
2021-09-30$103.62M$7.84M$98.67M$50.50M$157.00M$334.00K$110.43M
2021-06-30$177.07M$1.14M$86.13M$28.78M$116.05M$53.00K$61.81M
2021-03-31$1.98M$0.00$134.87M$25.74M$160.61M$196.00K-$168.91M
2020-12-31$1.73M(m)(m)(m)$110.14M(m)-$105.65M
2020-09-30$1.93M$0.00$70.68M$18.86M$89.54M$22.00K-$84.61M
2020-06-30$66.99M$0.00$79.65M$16.39M$96.04M$46.00K-$31.17M
2020-03-31$5.72M(m)$64.98M(m)$77.63M$16.00K-$77.24M
2019-12-31$980.00K(m)(m)(m)$64.74M(m)-$63.77M
2019-09-30$1.40M(m)$39.86M(m)$49.08M-$13.00K-$48.31M
2019-06-30$2.05M(m)$29.80M(m)$37.82M$19.00K-$33.93M
2019-03-31$3.66M(m)$25.87M(m)$34.43M(m)-$28.67M
2018-12-31$3.13M(m)(m)(m)$29.92M(m)-$26.39M
2018-09-30$2.88M(m)$29.84M(m)$37.23M(m)-$33.46M
2018-06-30$2.22M(m)(m)(m)$27.22M(m)-$24.45M
2018-03-31$2.43M(m)(m)(m)$34.99M(m)-$31.59M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$238.92M$0.00$244.21M$53.53M(m)$349.00K-$45.62M
2025-06-30$4.25M$11.00K$216.15M$46.23M(m)$186.00K-$231.92M
2024-06-30$59.45M$111.00K$205.24M$66.59M(m)-$1.24M-$203.65M
2023-06-30$66.75M$1.93M$325.73M$92.29M(m)-$5.08M-$335.68M
2022-06-30$1.19B$118.07M$205.31M$79.84M(m)$246.06M$442.13M
2021-06-30$179.05M$1.15M$221.00M$54.52M$276.67M$249.00K-$107.10M
2020-06-30$72.71M$0.00$144.63M$29.04M$173.67M$62.00K-$108.41M
2019-06-30$5.71M(m)$55.68M(m)$72.25M$19.00K-$62.60M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$4.49M(m)$367.62M$68.46M(m)$354.00K-$395.06M
2024-09-30$61.83M$161.00K$400.42M$92.33M(m)-$1.06M-$417.37M
2023-09-30$69.39M$1.97M$470.75M$133.22M(m)-$8.29M-$499.09M
2022-09-30$1.57B$140.32M$319.48M$123.02M(m)$288.48M$617.44M
2021-09-30$282.67M$8.99M$319.67M$105.02M$433.67M$583.00K$3.33M
2020-09-30$74.63M$0.00$215.32M$47.89M$263.21M$84.00K-$193.02M
2019-09-30$7.11M(m)$95.54M(m)$121.33M$5.00K-$110.91M
2018-09-30$7.54M(m)$78.26M(m)$99.44M-$500.00K-$89.49M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$68.56M$26.00K$455.97M$92.07M(m)$217.00K-$437.99M
2024-12-31$74.20M$845.00K$506.50M$119.03M(m)-$1.15M-$521.96M
2023-12-31$86.18M$2.77M$579.72M$174.44M(m)-$13.08M-$615.12M
2022-12-31$1.62B$146.32M$474.65M$161.76M(m)$238.44M$515.84M
2021-12-31$1.10B$65.86M$448.01M$160.79M(m)$21.22M$528.58M
2020-12-31$76.37M$0.00$302.41M$70.94M$373.35M$54.00K-$298.67M
2019-12-31$8.09M$0.00$148.47M$37.60M$186.07M$154.00K-$174.68M
2018-12-31$10.67M(m)$100.23M(m)$129.36M-$480.00K-$115.88M
2017-12-31$2.71M(m)$62.51M(m)$84.20M-$10.92M-$69.85M

Similar stocks

Stock NameCountryMarket CapPE Ratio
NOVAVAX INC (NVAX)United States$1.748B-6.26
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Vericel Corp (VCEL)United States$2.011B93.97
Immunocore Holdings plc (IMCR)$1.613B-90.43
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40